Đang chuẩn bị liên kết để tải về tài liệu:
Radiotherapy of abdomen with precise renal assessment with SPECT/CT imaging (RAPRASI): Design and methodology of a prospective trial to improve the understanding of kidney radiation dose response

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

The kidneys are a principal dose-limiting organ in radiotherapy for upper abdominal cancers. The current understanding of kidney radiation dose response is rudimentary. More precise dose-volume response models that allow direct correlation of delivered radiation dose with spatio-temporal changes in kidney function may improve radiotherapy treatment planning for upper-abdominal tumours. |

TÀI LIỆU LIÊN QUAN

The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: Based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume

Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: A meta-analysis of randomized controlled trials

Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: A propensity-matched analysis

Combined kyphoplasty and intraoperative radiotherapy (Kypho-IORT) versus external beam radiotherapy (EBRT) for painful vertebral metastases - a randomized phase III study

Which nasopharyngeal cancer patients need adaptive radiotherapy?

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)

New Technologies in Radiation Oncology

Treatment results of locally advanced cervical cancer by external beam radiotherapy and low dose rate brachytherapy at Hue Central Hospital

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.